IP Library Granted Patent US 9,758,510
Granted Patent B2
US 9,758,510 · App. 15/162,887 · Granted Sep 12, 2017

Modulators of ATP-binding cassette transporters

Inventors: Sara S. Hadida Ruah (La Jolla, CA); Jinglan Zhou (San Diego, CA); Brian Bear (Oceanside, CA); Mark T. Miller (San Diego, CA); Jason McCartney (Cardiff by the Sea, CA); Mehdi Michel Jamel Numa (San Diego, CA)
Assignee: Vertex Pharmaceuticals Incorporated
C07D405/12C07B59/002C07D403/12C07D405/14C07D471/04C07D487/04G01N33/5008G01N33/6872C07B2200/05G01N2333/705G01N2500/02G01N2500/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,758,510
App. No.
15/162,887
Granted
Sep 12, 2017
Kind
B2
Abstract

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Claims (30)

1. A process of preparing compounds of the following formula Ic:

wherein,

R 1 is —Z A R 4 , wherein each Z A is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z A are optionally and independently replaced by —CO—, —CS—, —CONR A —, —CONR A NR A —, —CO 2 —, —OCO—,

—NR A CO 2 —, —O—, —NR A CONR A —, —OCONR A —, —NR A NR A —, —NR A CO—, —S—, —SO—, —SO 2 —, —NR A —, —SO 2 NR A —, —NR A SO 2 —, or —NR A SO 2 NR A —,

Each R 4 is independently R A , halo, —OH, —NH 2 , —NO 2 , —CN, or —OCF 3 ,

Each R A is independently hydrogen, an optionally substituted aliphatic, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl;

Each R 2 is independently —Z B R 5 , wherein each Z B is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z 8 are optionally and independently replaced by —CO—, —CS—, —CONR B —, —CONR B NR B —, —CO 2 —, —OCO—, —NR B CO 2 —, —O—, —NR B CONR B —, OCONR B —, —NR B NR B —, —NR B CO—, —S—, SO—, —SO 2 —, —NR B —, —SO 2 NR B —, —NR B SO 2 —, or —NR B SO 2 NR B —,

Each R 5 is independently R B , halo, —OH, —NH 2 , —NO 2 , —CN, —CF 3 , or —OCF 3 ,

Each R B is independently hydrogen, an optionally substituted aliphatic, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl,

Or, any two adjacent R 2 groups together with the atoms to which they are attached form an optionally substituted carbocycle or an optionally substituted heterocycle;

Ring A is an optionally substituted 3-7 membered monocyclic ring having 0-3 heteroatoms selected from N, O, and S;

Ring B is a group having formula Ia:

or a pharmaceutically acceptable salt thereof, wherein

p is 0-2,

Each R 3 and R′ 3 is independently —Z C R 6 , where each Z C is independently a bond or an optionally substituted branched or straight C 1-6 aliphatic chain wherein up to two carbon units of Z C are optionally and independently replaced by —CO—, —CS—, —CONR C —, —CONR C NR C —, —CO 2 —, —OCO—, —NR C CO 2 —, —O—, —NR C CONR C —, —OCONR C —, —NR C NR C —, —NR C CO—, —S—, —SO—, —SO 2 —, —NR C —, —SO 2 NR C —, —NR C SO 2 —, or —NR C SO 2 NR C —,

Each R 6 is independently R C , halo, —OH, —NH 2 , —NO 2 , —CN, or —OCF 3 ,

Each R C is independently hydrogen, an optionally substituted aliphatic, an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl,

Or, any two adjacent R 3 groups together with the atoms to which they are attached form an optionally substituted heterocycle; and

n is 1-3;

comprising converting the acid of the following formula:

to the corresponding acid chloride of the following formula:

wherein R 2 , n, and ring A are as defined above, and

coupling the acid chloride with an amine of the following formula:

wherein R 1 and Ring B are as defined above

or alternatively, reacting the acid with a coupling reagent to provide an active ester and coupling the active ester with an amine of the aforementioned formula.

2. The process of claim 1 , wherein n is 2 and two adjacent R 2 groups together with the atoms to which they are attached form an optionally substituted heterocycle.

3. The process of claim 2 , wherein n is 2 and two adjacent R 2 groups together with the atoms to which they are attached form

ring A is a cyclopropyl ring;

R 1 is H;

p is 2 and one R 3 is halo or H and the other R 3 is —C(CH 3 ) 2 CH 2 OH; and R′ 3 is —CH 2 CH(OH)CH 2 OH.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2017
From: HADIDA RUAH, SARA S.; GROOTENHUIS, PETER D.J.; VAN GOOR, FREDERICK; ZHOU, JINGLAN; BEAR, BRIAN; MILLER, MARK T.; MCCARTNEY, JASON; NUMA, MEHDI MICHEL JAMEL; YANG, XIAOQING
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 042970/0642 →
CHANGE OF ADDRESS Recorded Jul 11, 2017
From: VERTEX PHARMACEUTICALS INCORPORATED
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 043151/0445 →
Continuity (6)
Continuation 14532791 · Nov 4, 2014
Continuation 14058839 · Oct 21, 2013
Continuation 12829879 · Jul 2, 2010
Division 11786001 · Apr 9, 2007
Provisional Application 60790459 · Apr 7, 2006
Related Publication 20160332997A1 · Nov 17, 2016